Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Our Patients
Focusing on the unmet medical needs of patients with rare disorders and their families
Our Company
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Latest News
07.07
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
Read More06.11
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
Read More